Zions Bancorporation ( ZION) numbers boosted at FBR Capital Markets. Shares now seen reaching $27. Estimates also raised, as the credit turnaround is gaining momentum. Outperform rating. Arch Coal ( ACI) estimates were raised through 2012 at FBR Capital Markets. Company had a weak quarter, but is seeing higher met coal volumes. Outperform rating and $39 price target. Atheros ( ATHR) estimates, target boosted at FBR Capital Markets. Shares now seen reaching $43. Company is seeing higher demand and gaining market share. Market Perform rating. Citigroup ( C) estimates, target increased at UBS. Shares now seen reaching $5. Estimates also raised, even though numbers should tail off from a strong first quarter. Neutral rating. Citigroup target, estimates raised at Barclays. Price target increased $1 to $6 after mixed first-quarter results. 2010 and 2011 EPS estimates lifted to 35 cents and 45 cents, respectively. Overweight rating. Corning ( GLW) target, estimates raised at Barclays. Price target increased $1 to $24. Expecting an earnings beat and raised guidance. 2010 and 2011 EPS estimates increased to $1.85 and $2.00, respectively. Halliburton ( HAL) estimates, target raised at Goldman Sachs. Estimates were increased through 2012. Company is seeing higher margins in North America, and international growth is around the corner. Buy rating and new $43 price target. Home Depot ( HD) numbers raised at FBR Capital Markets. Shares now seen reaching $40, according to FBR Capital Markets. Estimates also increased, as checks suggest the company is seeing higher sales trends. Outperform rating. IBM ( IBM) numbers boosted at Barclays. IBM 2010 and 2011 EPS estimates raised to $11.22 and $12.40, respectively, as company's first quarter was in line with expectations. Maintain Equal Weight rating and $145 price target. IBM estimates boosted at Goldman Sachs through 2012. Company is seeing higher sales, but currency trends are adding to costs. Neutral rating and $140 price target. Eli Lilly ( LLY) numbers cut at Barclays. 2010 and 2011 EPS estimates sunk to $4.49 and $4.29, respectively. 35-cent negative impact to EPS from health care reform. Maintain Equal Weight rating and $39 price target. Eli Lilly estimates lowered at Goldman were cut through 2012 at Goldman Sachs. Company will see lower sales, given health care reform. Sell rating and $34 price target. Lowe's ( LOW) estimates, target boosted at FBR Capital Markets. Estimates were raised through 2011. Company is likely seeing better sales trends. Outperform rating and new $30 price target. Lam Research ( LRCX) numbers boosted at UBS through 2011. Company should benefit from higher memory cap-ex spending. Buy rating and new $52 price target. MGM Mirage ( MGM) added to Conviction Buy list at Goldman Sachs. Decline following the convertible offering has created an attractive buying opportunity. $17.50 price target. Monsanto ( MON) target, estimates cut at Credit Suisse. Price target lowered to $72 from $86 on higher competition. 2010 and 2011 EPS estimates trimmed to $3.13 and $3.58, respectively. Maintain Neutral rating. M&T Bank ( MTB) estimates, target upped at FBR Capital Markets. Estimates were increased through 2011. Company is seeing lower credit costs and improving capital ratios. Market Perform rating and new $82 price target. Standard Pacific ( SPG) numbers boosted at UBS. Estimates were raised through 2011. Company is finding lots at attractive prices and community growth should accelerate. Neutral rating and new $5.25 price target. Trina Solar Limited ( TSL) target raised at Barclays, although estimates are mixed. Price target increased to $27 from $25 as second-half 2010 estimates appear conservative. 2010 EPS estimates cut to $2.49. 2011 EPS estimate raised to $2.04. Equal Weight rating. United Technologies ( UTX) target upped at UBS. Shares now seen reaching $82. Company has lagged its peers but should catch up as the economic recovery continues. Buy rating. Werner Enterprises ( WERN) estimates lowered at FBR Capital Markets. Estimates were reduced through 2011. Company is seeing softer pricing. Market Perform rating and $25 price target.